Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Comment by Steveminon Oct 06, 2021 1:13pm
138 Views
Post# 33974113

RE:RE:The duty of Loyalty for a CEO

RE:RE:The duty of Loyalty for a CEOI  applaude your positivity, however how many times over the years have you heard Inmed investors say:
"There are good things happening"
"Now is a great time to buy"
"See you at fifty"
Blah, blah, blah.....

Doesn't matter what is happening at Inmed - Adams can't execute anything. We've witnessed it for years. He failed. It's time to bring someone in who can push the ball down the field and actually get things done in a timely manner.

As for bringing products to market, Shane Johnson (Baymedica) said that the sales staff consists of him, that's it, no one else. So, even if they are able to bring something to market, they will have to develop a sales plan and hire sales and management for it. God knows, this could take Adams a year to do - or longer. Who knows.

And as far as cannabinoid manufacturing, you missed my point. Adams said all along that Integrasyn would be able to produce pharma grade AND consumer grade faster, cheaper and more efficiently than anyone else. Now all of the sudden that's not the case? Sounds fishy to me.

The whole point is the market (and big investors) will continue to shrug at any news from Inmed because the track record shows deep failures and lack of transparency from management. If you bring in a new CEO who delivers on goals and does what they say they are going to do, then Inmed will see a massive sp increase.

The days of low energy, kick the can, "don't question me just leave me alone" Eric Adams are over. Plain and simple.
<< Previous
Bullboard Posts
Next >>